600079.SS
Humanwell Healthcare (Group) Co.,Ltd. [600079.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600079.SS Stock Summary
Top 10 Correlated ETFs
600079.SS
Top 10 Correlated Stocks
600079.SS
In the News
600079.SS Financial details
Company Rating
Strong Buy
Market Cap
37.24B
Income
2.43B
Revenue
24.14B
Book val./share
9.99
Cash/share
3.07
Dividend
0.16
Dividend %
0.66%
Employees
16.07K
Optionable
No
Shortable
Yes
Earnings
24 Aug 2023
P/E
16.13
Forward P/E
-
PEG
5.62
P/S
1.64
P/B
2.42
P/C
7.88
P/FCF
41.87
Quick Ratio
1.08
Current Ratio
1.32
Debt / Equity
0.62
LT Debt / Equity
0.11
-
-
EPS (TTM)
1.48
EPS next Y
-
EPS next Q
-
EPS this Y
33.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
3.39%
Revenue Q/Q
-1.1%
EPS Q/Q
-
-
-
-
-
SMA20
4.35%
SMA50
-4%
SMA100
-11.11%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
16%
ROC
0.15%
Gross Margin
45%
Oper. Margin
14%
Profit Margin
10%
Payout
31%
Shs Outstand
1.63B
Shs Float
972.45M
-
-
-
-
Target Price
-
52W Range
15.92-28.92
52W High
-13.61%
52W Low
+61.27%
RSI
54
Rel Volume
1.34
Avg Volume
15.5M
Volume
20.82M
Perf Week
-2.3%
Perf Month
6.24%
Perf Quarter
-9.74%
Perf Half Y
-1.18%
-
-
-
-
Beta
0.793882
-
-
Volatility
0.6%, 0.86%
Prev Close
1.13%
Price
24.19
Change
1.51%
600079.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 14.52 | 15.25 | 15.01 | 12.95 | 13.85 | |
| Net income per share | -1.82 | 0.91 | 1.19 | 1.15 | 1.54 | |
| Operating cash flow per share | 0.46 | 1.4 | 1.44 | 1.37 | 1.51 | |
| Free cash flow per share | -0.56 | 0.84 | 0.65 | 0.3 | -0.42 | |
| Cash per share | 2.19 | 2.97 | 4.5 | 3.84 | 3.8 | |
| Book value per share | 8.31 | 7 | 7.72 | 8.16 | 9.32 | |
| Tangible book value per share | 5.61 | 5.03 | 7.2 | 7.51 | 8.81 | |
| Share holders equity per share | 8.31 | 7 | 7.72 | 8.16 | 9.32 | |
| Interest debt per share | 9.52 | 8.95 | 10.31 | 8.9 | 6.65 | |
| Market cap | 12.77B | 19.63B | 46.68B | 35.74B | 38.54B | |
| Enterprise value | 20.27B | 28.2B | 54.67B | 43.54B | 43.61B | |
| P/E ratio | -5.38 | 14.92 | 28.42 | 19.66 | 15.51 | |
| Price to sales ratio | 0.68 | 0.89 | 2.26 | 1.74 | 1.73 | |
| POCF ratio | 21.17 | 9.63 | 23.47 | 16.4 | 15.79 | |
| PFCF ratio | -17.45 | 16.13 | 52.41 | 75.11 | -57.32 | |
| P/B Ratio | 1.18 | 1.93 | 4.39 | 2.76 | 2.56 | |
| PTB ratio | 1.18 | 1.93 | 4.39 | 2.76 | 2.56 | |
| EV to sales | 1.07 | 1.27 | 2.64 | 2.12 | 1.95 | |
| Enterprise value over EBITDA | 6.68 | 8.15 | 14.95 | 10.57 | 9.39 | |
| EV to operating cash flow | 33.61 | 13.84 | 27.49 | 19.98 | 17.86 | |
| EV to free cash flow | -27.7 | 23.18 | 61.39 | 91.51 | -64.87 | |
| Earnings yield | -0.19 | 0.07 | 0.04 | 0.05 | 0.06 | |
| Free cash flow yield | -0.06 | 0.06 | 0.02 | 0.01 | -0.02 | |
| Debt to equity | 1.08 | 1.19 | 1.26 | 1 | 0.68 | |
| Debt to assets | 0.32 | 0.34 | 0.41 | 0.37 | 0.28 | |
| Net debt to EBITDA | 2.47 | 2.48 | 2.18 | 1.89 | 1.09 | |
| Current ratio | 1 | 1.08 | 1.28 | 1.17 | 1.28 | |
| Interest coverage | -2.02 | 3.38 | 3.84 | 2.97 | 7.38 | |
| Income quality | -0.31 | 1.51 | 1.15 | 1.2 | 0.79 | |
| Dividend Yield | 0.08 | 0.05 | 0.02 | 0.02 | 0.02 | |
| Payout ratio | -0.44 | 0.75 | 0.43 | 0.37 | 0.25 | |
| Sales general and administrative to revenue | 0.03 | 0.02 | 0.03 | -0.02 | 0.02 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | |
| Intangibles to total assets | 0.2 | 0.19 | 0.09 | 0.11 | 0.1 | |
| Capex to operating cash flow | -2.21 | -0.4 | -0.55 | -0.78 | -1.28 | |
| Capex to revenue | -0.07 | -0.04 | -0.05 | -0.08 | -0.14 | |
| Capex to depreciation | -2.44 | -1.42 | -1.7 | -2.51 | -4.16 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 18.45 | 11.94 | 14.39 | 14.5 | 17.97 | |
| ROIC | -0.09 | 0.1 | 0.1 | 0.11 | 0.12 | |
| Return on tangible assets | -0.08 | 0.05 | 0.06 | 0.06 | 0.08 | |
| Graham Net | -7.87 | -5.87 | -4.24 | -3.46 | -1.91 | |
| Working capital | 58.78M | 1.3B | 3.75B | 2.59B | 4.29B | |
| Tangible asset value | 7.3B | 7.3B | 9.91B | 11.91B | 14.22B | |
| Net current asset value | -4.7B | -4.24B | -2.39B | -1.6B | 1.35B | |
| Invested capital | 1.08 | 1.19 | 1.26 | 1 | 0.68 | |
| Average receivables | 8.54B | 9.46B | 8.87B | 8.44B | 9.18B | |
| Average payables | 2.99B | 3.42B | 2.94B | 2.54B | 3.07B | |
| Average inventory | 3B | 3.38B | 3.07B | 2.89B | 3.27B | |
| Days sales outstanding | 178.94 | 159.03 | 142.7 | 156.3 | 156.08 | |
| Days payables outstanding | 107.01 | 94.1 | 72.88 | 83.37 | 99.79 | |
| Days of inventory on hand | 104.62 | 94.18 | 80.81 | 97 | 98.97 | |
| Receivables turnover | 2.04 | 2.3 | 2.56 | 2.34 | 2.34 | |
| Payables turnover | 3.41 | 3.88 | 5.01 | 4.38 | 3.66 | |
| Inventory turnover | 3.49 | 3.88 | 4.52 | 3.76 | 3.69 | |
| ROE | -0.22 | 0.13 | 0.15 | 0.14 | 0.17 | |
| Capex per share | -1.02 | -0.57 | -0.8 | -1.07 | -1.93 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.35 | 3.53 | 3.77 | 3.84 | 3.79 | |
| Net income per share | 0.49 | 0.45 | 0.24 | 0.41 | 0.41 | |
| Operating cash flow per share | 0.49 | 0.45 | 0.24 | 0.41 | 0.56 | |
| Free cash flow per share | 0.27 | 0.21 | -0.05 | 0.16 | 0.26 | |
| Cash per share | 2.53 | 3.1 | 3.79 | 2.55 | 3.07 | |
| Book value per share | 8.85 | 9.33 | 9.31 | 9.7 | 9.99 | |
| Tangible book value per share | 8.18 | 8.66 | 8.8 | 9.26 | 9.53 | |
| Share holders equity per share | 8.85 | 9.33 | 9.31 | 9.7 | 9.99 | |
| Interest debt per share | 7.57 | 6.42 | 6.4 | 5.64 | 6.25 | |
| Market cap | 25.73B | 28.19B | 38.59B | 43.46B | 43.72B | |
| Enterprise value | 34.39B | 34.61B | 43.66B | 49.28B | 49.69B | |
| P/E ratio | 8.1 | 9.76 | 24.89 | 16.33 | 16.6 | |
| Price to sales ratio | 4.77 | 4.97 | 6.35 | 6.98 | 7.1 | |
| POCF ratio | 32.39 | 39.06 | 99.58 | 65.32 | 48.41 | |
| PFCF ratio | 58.56 | 83.6 | -454.46 | 165.1 | 102.22 | |
| P/B Ratio | 1.81 | 1.88 | 2.57 | 2.76 | 2.7 | |
| PTB ratio | 1.81 | 1.88 | 2.57 | 2.76 | 2.7 | |
| EV to sales | 6.38 | 6.1 | 7.18 | 7.92 | 8.07 | |
| Enterprise value over EBITDA | 28.25 | 38.38 | 89.03 | 47.82 | 44.25 | |
| EV to operating cash flow | 43.29 | 47.94 | 112.66 | 74.08 | 55.03 | |
| EV to free cash flow | 78.26 | 102.63 | -514.18 | 187.24 | 116.2 | |
| Earnings yield | 0.03 | 0.03 | 0.01 | 0.02 | 0.02 | |
| Free cash flow yield | 0.02 | 0.01 | 0 | 0.01 | 0.01 | |
| Debt to equity | 0.83 | 0.7 | 0.68 | 0.58 | 0.62 | |
| Debt to assets | 0.33 | 0.3 | 0.28 | 0.26 | 0.27 | |
| Net debt to EBITDA | 7.11 | 7.12 | 10.34 | 5.65 | 5.32 | |
| Current ratio | 1.15 | 1.26 | 1.28 | 1.36 | 1.32 | |
| Interest coverage | 2.51 | -7.85 | 4.34 | 10.73 | 12.56 | |
| Income quality | 1 | 1 | 1 | 1 | 0 | |
| Dividend Yield | 0.01 | 0.01 | 0 | 0 | 0.01 | |
| Payout ratio | 0.17 | 0.39 | 0.23 | 0.15 | 0.45 | |
| Sales general and administrative to revenue | -0.11 | 0.22 | -0.1 | 0.06 | -0.02 | |
| Research and developement to revenue | 0.04 | 0.04 | 0.05 | 0.05 | 0.06 | |
| Intangibles to total assets | 0.11 | 0.11 | 0.1 | 0.11 | 0.09 | |
| Capex to operating cash flow | -0.45 | -0.53 | -1.22 | -0.6 | -0.53 | |
| Capex to revenue | -0.07 | -0.07 | -0.08 | -0.06 | -0.08 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 9.92 | 9.7 | 7.09 | 9.46 | 9.55 | |
| ROIC | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | |
| Return on tangible assets | 0.03 | 0.02 | 0.01 | 0.02 | 0.02 | |
| Graham Net | -3.39 | -1.89 | -1.91 | -1.7 | -1.74 | |
| Working capital | 2.27B | 3.89B | 4.29B | 4.9B | 4.76B | |
| Tangible asset value | 13.16B | 13.93B | 14.22B | 15.02B | 15.46B | |
| Net current asset value | -1.25B | 1.23B | 1.35B | 1.9B | 1.81B | |
| Invested capital | 0.83 | 0.7 | 0.68 | 0.58 | 0.62 | |
| Average receivables | 10.22B | 10.14B | 9.97B | 10.19B | 11.05B | |
| Average payables | 2.79B | 2.91B | 3.2B | 3.53B | 3.74B | |
| Average inventory | 3.21B | 3.21B | 3.31B | 3.37B | 3.35B | |
| Days sales outstanding | 165.13 | 164.57 | 141.34 | 156.53 | 164.87 | |
| Days payables outstanding | 83.54 | 82.17 | 90.85 | 97.32 | 102.26 | |
| Days of inventory on hand | 93.76 | 89.08 | 90.11 | 89.66 | 89.42 | |
| Receivables turnover | 0.55 | 0.55 | 0.64 | 0.57 | 0.55 | |
| Payables turnover | 1.08 | 1.1 | 0.99 | 0.92 | 0.88 | |
| Inventory turnover | 0.96 | 1.01 | 1 | 1 | 1.01 | |
| ROE | 0.06 | 0.05 | 0.03 | 0.04 | 0.04 | |
| Capex per share | -0.22 | -0.24 | -0.29 | -0.25 | -0.29 |
600079.SS Frequently Asked Questions
What is Humanwell Healthcare (Group) Co.,Ltd. stock symbol ?
Humanwell Healthcare (Group) Co.,Ltd. is a CN stock and trading under the symbol 600079.SS
What is Humanwell Healthcare (Group) Co.,Ltd. stock quote today ?
Humanwell Healthcare (Group) Co.,Ltd. stock price is $24.19 today.
Is Humanwell Healthcare (Group) Co.,Ltd. stock public?
Yes, Humanwell Healthcare (Group) Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 15.5M
- Market Capitalization 37.24B
- Employee 16.07K
- CEO Mr. Xiafei Deng
- Headquarters Wuhan,CN
- IPO Date 1997-06-06
-
Website
https://www.humanwell.com.cn 
Humanwell Healthcare (Group) Co.,Ltd. provides healthcare solutions in the Asia Pacific, North America, Africa, and internationally. The company offers anesthetic/analgesic products; women's health products for unplanned pregnancy, emergency contraception, and birth control; consumer healthcare products for women; and CNS drugs for bronchitis, migraine, dysmenorrhea, neuralgia, epilepsy, acute and chronic cerebrovascular diseases, and brain injury and peripheral vascular diseases. It also provides herbal medicines for cold and flu, rheumatoid arthritis, skin care, hepatitis, urinary tract infection, and hypomnesis; anti-infection drugs; OTC medicines for digestive disorders, cold and flu, anti-inflammation, anti-infection, and nutritional supplements; and other products targeting cardiovascular, gastrointestinal, and reproductive diseases. The company was formerly known as Wuhan Humanwell Healthcare (Group) Co., Ltd. and changed its name to Humanwell Healthcare (Group) Co.,Ltd. in March 2013. Humanwell Healthcare (Group) Co.,Ltd. was founded in 1993 and is based in Wuhan, China.
